What We're Reading: Page 377
Industry reads hand-picked by our editors
Nov 24, 2014
-
Reuters
Sacré bleu! Sovaldi to cost 38.8% less in France than in US
-
-
Sanofi can't shake its diabetes business blues—and investors aren't happy
-
-
The 14 best-performing CEOs in biotech and pharma
-
Judge refuses to block Ranbaxy's generic competitors
-
-
EMA's updated conflict of interest policy reflects pragmatism, flexibility
-
-
Purdue joins burgeoning abuse-deterrent pain pill field with Hysingla approval
Nov 21, 2014
-
These execs are on Sanofi's CEO short list
-
-
US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark
-
-
-
In massive transparency effort, feds push for failed clinical trial data reporting
-
-
Novartis aims to put more 'tech' in biotech
-
Goodbye Philly, hello Boston: Shire moves US HQ, 500 jobs
-
Another first: Gilead spends $125M on priority review voucher for mystery drug
Nov 20, 2014
-
-
HHS scraps regulations for 340B drug pricing program
-
-
India's Ranbaxy sues FDA for yanking Nexium, Valcyte generics approval
-
Plot twist: Controversial Merck cholesterol drugs Zetia, Vytorin work
-
Regeneron/Sanofi PCSK9 inhibitor could become cholesterol top dog
-
-
Rainmaker: Gilead's Harvoni approved in the EU
-
-
Has the price of developing drugs really doubled in the last 11 years?
Nov 19, 2014
-
HHS scraps regulations for 340B drug pricing program
-
-
Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
-
-
Merck dances: Keytruda more than doubles PFS in some melanoma patients
-
-
How pharma has improved patients' access to drugs since 2012
-
-
FDA commish to talk drug safety at China regulatory chief confab
-
Nov 18, 2014
-
-
Cancer immunotherapy specialist Juno Therapeutics files for IPO
-
UPDATED: Actavis buys Allergan for $66 billion
-
-
-
Finally: FDA reverses course, OKs Sanofi's Lemtrada for MS
-
Another big win for Roche as Avastin nabs FDA ovarian cancer indication
-
-
-
EU's top drug regulator forced out by EMA panel
Nov 17, 2014
-
AstraZeneca in preclinical development for Brilinta reversal agent
-
-
Apollo Global Manangement joins bidding wars for GSK's mature drugs
-
-
FDA approves new Invega indication for schizoaffective disorder
-
-
Pfizer, Gates Foundation team up to get injectable contraceptives to poor countries
-
-
FDA has concerns over bioequivalence of two Concerta generics
-
Japanese transparency data raises eyebrows about pharma spending
Nov 14, 2014
-
-
Let's make a deal: Allergan, Actavis talk $60 billion merger
-
-
Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder
-
-
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
-
Indian pharma really feeling the pain of lagging US generic approvals
-
GSK applying for expanded Revolade indication in the EU
-
No more half measures: Senate to add Ebola to priority review program
-
Advaxis wants to investigate a compound for head & neck HPV-related cancers
Previous
